PF-2545920 clinical trials
Also written PF-02545920.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How each study uses PF-2545920 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- PF-02545920
- 9
Studies by the year they started
9 studies that test it; most in 2013 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 3 |
| 2014 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses PF-2545920 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With SchizophreniaCompletedPhase 1PfizerNCT00463372Written as PF-02545920
- A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With SchizophreniaCompletedPhase 1PfizerNCT01829048Written as PF-02545920
- An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of SchizophreniaCompletedPhase 2PfizerNCT01175135Written as PF-02545920
- Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's DiseaseCompletedPhase 2PfizerNCT01806896Written as PF-02545920
- Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's DiseaseCompletedPhase 2PfizerNCT02197130Written as PF-02545920
- An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of SchizophreniaTerminatedPhase 2PfizerNCT01939548Written as PF-02545920
- A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male VolunteersCompletedPhase 1PfizerNCT01918202Written as 20 mg PF-02545920
- Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy SubjectsTerminatedPhase 1PfizerNCT01244880Written as PF-02545920
- Evaluation Of Striatal Glucose Metabolism With Positron Emission Tomography Following PF-02545920 In Healthy SubjectsCompletedPhase 1PfizerNCT01103726Written as PF-02545920
Codes
What other systems call PF-2545920 · ClinicalTrials.gg INT005519
- UNII (FDA) R9Y8EY0G42MARDEPODECTConfirmed FDA, Wikidata
- Wikidata Q7119048PF-2545920Confirmed FDA, Wikidata
- Wikidata Q72500737PF-2545920Confirmed FDA, Wikidata
- DrugBank DB08387One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | R9Y8EY0G42 | MARDEPODECT | Confirmed FDA, Wikidata |
| Wikidata | Q7119048 | PF-2545920 | Confirmed FDA, Wikidata |
| Wikidata | Q72500737 | PF-2545920 | Confirmed FDA, Wikidata |
| DrugBank | DB08387 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.